Catalyst Pharmaceutical CPRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Agamree | $131.76M+12.5% | $117.09M+13.8% | $102.86M+20.3% | $85.53M+27.8% | $66.91M+45.3% | |
| Firdapse | $373.51M+4.2% | $358.38M+4.4% | $343.28M+3.9% | $330.4M+2.3% | $322.92M+5.5% | |
| Fycompa | $91.49M-19.3% | $113.34M-14.1% | $131.98M-5.9% | $140.25M-1.5% | $142.45M+3.8% | |
| Product Revenue Net | $596.75M+1.3% | $588.81M+1.8% | $578.11M+3.9% | $556.17M+4.5% | $532.29M+8.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Catalyst Pharmaceutical break its business down?
- Catalyst Pharmaceutical (CPRX) reports revenue by product across 4 parts — Agamree, Firdapse, Fycompa and Product Revenue Net. Each is extracted from the segment footnotes and tracked over time.
- Where does Catalyst Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Catalyst Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.